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Introduction
Agaricus blazei Murill, an edible mushroom, shows
immunomodulatory and antitumor activities (1–5). In Brazil,
this fungus is used as a traditional medicine for the pre-
vention of cancer, diabetes, hyperlipidemia, arteriosclerosis
and chronic hepatitis. The polysaccharides, proteoglycans,
polysaccharide–protein complexes, glycoproteins and steroids
from Agaricus blazei Murill mycelia and fruiting body extracts
possess antitumor cytotoxic activities (3–10). However, the
mechanisms of the antitumor functions of these mushroom
components have yet to be determined. The bacterial lipo-
polysaccharide, mycoplasma lipopeptide (MALP-2), interacts
with toll-like receptors (TLRs) and induces cytokine produc-
tion. Similarly, Dectin-1, a fungal  -glucan receptor subunit,
has been shown to interact with TLR2 and mediate cell
activation (11,12). Agaricus blazei extract was shown to induce
cytokine (IL-12) gene expression. Based on these observations,
we hypothesized that Agaricus blazei Murill fraction H (ABH)
may interact with TLRs and induce signals for IL-12 produc-
tion. The specific objectives of this investigation were: (i) to
identify the characteristics of the cell population in peripheral
blood mononuclear cells (PBMC) stimulated by ABH; (ii) to
determine the optimal concentration of ABH required to induce
cytokine production in vitro; (iii) to identify the nature of TLR
interacting with ABH on the cell surface; and (iv) to evaluate
the influence of ABH on natural killer (NK) cell activity.
Subjects and Methods
Preparation of A.blazei Extracts
After 2 weeks in culture, A.blazei mycelia were digested with
hemicellulase for 1 h at 45 C. Then, the enzymes were inactiv-
ated at 70 C and freeze-dried. This compound is similar to
Agaricus Blazei Practical Compound (ABPC; Japan Applied
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ABPC products were made from this compound. Samples of
1.5 g of A.blazei compound were ground and mixed with distilled
water to a final concentration of 0.1 g/ml (w/v). After centrifuga-
tion, the supernatant was collected and passed through a 0.45  m
filter (Millipore Co., Bedford, MA) for use in the experiments.
Preparation of PBMCs
Heparinized human peripheral blood was obtained from
healthy donors. PBMCs were isolated using the Ficoll-
Hypaque density-gradient method, as described previously
(13). Peripheral blood was centrifuged at 2000 r.p.m. for
10 min to remove plasma. Blood cells were diluted with
phosphate buffered saline (PBS), then overlaid onto Ficoll-
Hypaque solution (Amersham Pharmacia Biotech UK Ltd.,
Buckinghamshire, UK) and centrifuged at 2000 r.p.m. for 30 min.
The PBMC layers were collected and washed twice with PBS.
The cells were resuspended to a concentration of 1   106cells/ml
in RPMI-1640 medium supplemented with 10% foetal calf
serum, 100 U/ml penicillin and 100  g/ml streptomycin.
Reagents and Monoclonal Antibodies (mAb)
Anti-human (h) TLR4 mAb HTA125 (mouse IgG2a) and
FITC-labelled HTA125 were purchased from BD Biosciences
Clontech (San Jose, CA) and eBioscience (San Diego, CA).
Anti-TLR2 mAb TL2.1 (mouse IgG2a) and FITC-labelled
TL2.1 were purchased from eBioscience and Cascade
Bioscience (Winchester, MA).
RNA Preparation Quantification and RNase
ProtectionAssay
After stimulation of human PBMC,total RNA was extracted from
the cells using TRIzol (Invitrogen Corp., Carlsbad, CA). RNase
protection assay was performed using the hCK-2RiboQuant
Multiprobe RNase Protection Assay system (BD Pharmingen,
San Jose, CA) according to the manufacturer’s instructions.
Aliquots of 10  g of RNA were used for each assay. Gels from
three distinct experiments were analyzed using a BAS3000
and Image Gage (Fuji Film, Tokyo, Japan).
Quantification of IL-12p40 and p70 in
Culture Supernatants
Isolated human PBMC were cultured in media containing
ABH, 1 ml of 10% FCS/RPMI1640 with various concentra-
tions of ABH, for 0–16 h. The levels of IL-12p40 in the super-
natants were measured using an enzyme-linked immunosorbent
assay (ELISA) kit, optEIATM ELISA kit (BD Pharmingen)
according to the manufacturer’s protocol. The concentration of
IL-12p40 and p70 was determined using the data analysis
program Softmax (Molecular Devices, Menlo Park, CA).
NK Activity Assay
NK activities of human PBMC and murine spleen cells were
determined by lactate dehydrogenase (LDH) assay. The NK-
sensitive mouse cell line YAC-1 was used as target cells. Target
and effector cells were mixed at the indicated effector/target
(E/T) ratios at 0.2 ml/well using 96-well round-bottomed multi-
well plates (BD Labware, Lincoln Park, NJ). After incubation
for 4 h, cells were centrifuged at 250 g for 4 min, and then the
cell-free supernatant was collected for LDH assay using
CytoTox96 (Promega, Madison, WI). The percentage of spe-
cific LDH release was calculated by the following formula:
% cytotoxicity   [(experimental LDH release)   (spontaneous
LDH release by effector and target)/(maximum LDH release)  
(spontaneous LDH release)]  100. For the control experiments,
the target cells were incubated either in culture medium alone to
determine spontaneous release or in a mixture of 2% Triton
X-100 to define the maximum LDH release. The spontaneous
release was always  10% of the maximum release. All assays
were performed in triplicate.
Results
Treatment of PBMC with ABH induced IL-12
Production
Expression of IL-12 messenger RNA (both p35 and p40 sub-
units) was determined in PBMC with or without ABH stimu-
lation by RNase protection assay. As shown in Figure 1, IL-12
messenger RNA expression (p40 subunit) was induced within
4 h after ABH stimulation. In unstimulated controls, IL-12
messenger RNA was not induced until 16 h. We quantified
the release of IL-12 p40 protein in human PBMC culture
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Figure 1. ABH induces IL-12 gene expression. Ficoll-isolated human
PBMCs were stimulated with 40 ng/ml ABH for the indicated times. RNase
protection assay was performed with total RNA from stimulated PBMC.
Aliquots of 10  g of RNA were used for each determination. Lane 1, free
probe; lane 2, yeast tRNA; lanes 3 and 4, unstimulated cells (–); lanes 5–8,
cells stimulated with Agaricus blazei extract for the times indicated at the top
of the panel. The upper panel shows IL-12p35 and p40 mRNA, and the lower
panel shows L32 and GAPDH as a control. Data shown are representative of
three independent experiments.eCAM 2004;1(3) 261
supernatants in relation to ABH dose. As shown in Figure 2A,
IL-12 p40 was induced significantly in all donors. The levels
of IL-12 production were reduced at concentrations of ABH in
excess of 170 ng/ml. Figure 2B shows induction of IL-12 p70
(heterodimer of p40 and p35) by ABH. These observations
suggest that ABH induces IL-12 production by PMBC.
CD14-positive Cells Produced IL-12 on Stimulation
with ABH
To determine the target population of ABH, we analyzed 
IL-12-production levels of each population by intracellular
cytokine staining method and flow cytometry. After 16-hour
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Figure 2. ABH induces IL-12p40 and p70. (A) Ficoll-isolated human PBMC (1   106/sample) were stimulated with ABH at various concentrations as indicated
at the bottom of the panels. After incubation for 16 h, supernatants were collected and the amounts of IL-12 p40 were determined. (B) PBMCs were stimulated
with 0.17 ng/ml ABH for 16 h. The supernatant was collected and the amounts of IL-12 p70 were determined. (A and B) IL-12 p40 and p70 in culture supernatants
were measured by ELISA. Data of IL-12 p40 and p70 shown are from four and two different donors, respectively.culture, only CD14 positive population was induced 
IL-12p40 (Figure 3). Neither normal media (control) nor
peripheral dendritic cells (lin-/CD11c and HLA-DR+) induced
production of IL-12 p40 protein (data not shown).
We then added anti-CD3/CD19 and CD14 monoclonal
antibody-conjugated Dynal beads to Ficoll PBMC fractions to
deplete each fractions. IL-12 production was observed in
PBMC from which CD3 and CD19 were depleted.
However, depletion of CD14 caused a 20% reduction in the
level of IL-12p40 production (Figure 4).
Involvement of CD14 and TLR4 in IL-12 Induction
byABH
Human TLRs have been shown to transduce intracellular
signals by some mycobacterial ligands. These reports suggest
that TLRs initiate human innate immune responses and pattern
recognition by TLRs regulates the nature of not only innate but
also adaptive immune responses (14–16).
Using neutralising antibodies (anti-hTLR4:HTA125, anti-
hTLR2:TL2.1 and anti-CD14), we examined whether TLR2,
TLR4 and CD14 are involved in the induction of IL-12 expres-
sion by ABPC. Preincubation of PBMC with anti-hTLR4 mAb
(HTA125) or anti-CD14 mAb (61D3) clearly inhibited IL-12
production in a dose-dependent manner. PBMC from three dif-
ferent donors were used, and the same results were observed in
all cases. In contrast, pre-treatment with anti-hTLR2 (TL2.1)
showed no effect (Fig. 5A).
Furthermore, flow cytometry was performed to quantify the
IL-12-producing cells. In PBMC pre-treated with anti-hTLR4
and anti-hCD14 monoclonal antibodies, the levels of IL-12
production by CD14-positive cells were reduced to 1.33% and to
0.19% in samples treated with anti-hTLR4 and anti-hCD14 mAb,
respectively. No effect was observed in samples treated with con-
trol antibody. There were no differences in the ratio of CD14-
positive cells in PBMC before and after antibody treatment
(Fig. 5B). These results suggested that anti-hTLR4 and anti-
hCD14 mAbs blocked signal transduction via TLR4 and CD14.
Induction of IL-12 by ABH was Not Inhibited
by Polymyxin B
CD14 and TLR4 have been reported as subunits of the
lipopolysaccharide (LPS) receptor complex. The CD14-TLR4-
MD2 heterotrimer recognises the LPS/LBP-complex (17–20).
Our results indicated that CD14 and TLR4 were essential
components for induction of IL-12 by ABH. To exclude the pos-
sibility that cellular activation by ABH was a result of endotoxin
contamination in the extracts, the abilities of ABH and refer-
ence LPS to induce IL-12 production by human PBMC were
examined in the presence and absence of polymyxin B.
Polymyxin B showed little effect on IL-12 induction by ABH,
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Figure 3. CD14-positive cells showed induction of IL-12. Human PBMC was stimulated with 0.17 ng/ml ABH for 16 h. IL-12 production was quantified by flow
cytometry (right panels). The flow cytometric data in the right panels represent three gated populations of CD14-positive and negative cells. Results of ABH
stimulated and unstimulated samples shown as open and closed histograms respectively. The region indicated by the bar represents IL-12-producing cells (shown
in left panels). Data shown are representative of three independent experiments.eCAM 2004;1(3) 263
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Figure 4. Depletion of CD14-positive cells reduced IL-12 production. (A) CD14-, CD3- or CD19-positive cells were depleted using beads conjugated with
monoclonal antibodies specific for each surface marker, as indicated at the top of the panels. After depletion, CD14-, CD3- and CD19-positive cells were
quantified by flow cytometry. (B) After treatment, PBMCs were stimulated with 0.17 ng/ml ABH for 16 h. Supernatants were examined by ELISA. Data shown
are representative of three independent experiments.whereas that of LPS was inhibited completely (Fig. 6). We
measured the amount of endotoxin in the ABH extract using an
Endospecy kit for endotoxin quantification (Seikagaku Corp.,
Tokyo, Japan). The ABH extract used in the present study was
essentially free from endotoxin contamination (data not shown).
ABH Extract Enhanced NK Activity
IL-12 is a critical factor in immune responses against pathogens
and tumors as it is the most potent promoter of type 1 responses
in CD4 T cells (Th1 responses). Th1 responses regulate
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Figure 5. Anti-CD14 and anti-TLR4 mono-
clonal antibodies neutralized the IL-12-inducing
effect of ABH. (A) PBMCs were pre-incubated
with anti-CD14, anti-TLR4, anti-TLR2 or con-
trol monoclonal antibody at four different doses
(1000, 100, 10, 1 ng). Agaricus blazei extract
was added after 4 h and incubation was
continued for 16 h. IL-12 p40 in supernatants
was quantified by ELISA. Data from three
independent donors are shown. (B) Cells pre-
treated with 1  g of control monoclonal anti-
body (b), 1  g of anti-CD14 antibody (c) or
1  g of anti-TLR4 antibody (d) were stimu-
lated with ABH for 16 h (b–d). Then, IL-12-
producing cells were quantified by flow
cytometry. Unstimulated PBMCs (a) were
included as controls. Data shown are representa-
tive of three independent experiments.eCAM 2004;1(3) 265
proliferation, interferon-  (IFN- ) production and cytotoxic
activities by T cells and natural killer cells (21–23). To evaluate
its effects in vivo, we examined the effect of oral administration
of ABH on NK cytotoxic activity of murine spleen cells.
ABH-treated mice showed significantly higher levels of NK
cytotoxic activity than controls; the ABH-treated group
showed 40% cytolysis, while the control group showed 25%
cytolysis (Fig. 7). This result suggested that oral administra-
tion of ABH can induce NK activity in vivo.
Discussion
Hemicellulase-digested  A.blazei extract showed a very high
degree of water solubility. Almost 95% by dry weight was
extracted in water, in contrast to non-digested samples, which
showed only about 20% extraction (data not shown). Various
methods were employed to extract the components from
A.blazei, including treatment with acid and organic solvent.
These methods for extraction were not suitable for evaluation and
analysis of total activity of all components of A.blazei. The high
degree of water solubility obtained by hemicellulase digestion is
a major advantage for analysis of the effects of Agaricus. In the
present study, we were able to analyze the total effect of Agaricus
extract as we could extract almost all of the components.
As the first step to determine the effects of ABH, we
attempted to identify inducible or suppressible cytokines.
We found the IL-12-inducing activity in the water extract. The
optimum concentration of ABH for induction of IL-12 was
from 170 to 510 ng/ml, and higher concentrations showed
lower levels of induction.
Agaricus blazei extract was reported previously to show a
suppressive effect against proliferation and cytokine expression
using PBMC (24). The effects of elements with the ability to
suppress cell activity may appear at high doses. Suppressive
elements did not have sufficient effects to suppress the
induction of IL-12 to  170 ng/ml.
The results of intracellular cytokine staining and population-
specific elimination showed CD14 positive cells, monocytes/
macrophages (Mo/M ) to be the target population of ABH.
We detected no IL-12 production by peripheral dendritic cells
(DC). Peripheral circulating Mo circulate for 1–3 days before
entering tissues, where they differentiate into mature resident
M  or DCs (25). Our results suggested that ABH possessed
the potential to activate immature Mo and promote the Th1
response in tissue. As a result of this activity, ABH maintains
the Th1 response level and cellular immunity. ABH-treated
mice have been reported to show higher levels of NK activity
in the spleen than untreated controls. The ability of DCs to
produce cytokines differs among DC subsets depending on
the tissue to which they belong (26,27). Peripheral Mo hetero-
geneity was reported previously (28–30). Thus, we speculate
that ABH may have different effects on different subsets of
Mo and DC. Therefore, the effects of ABH should be analyzed
from various viewpoints.
Various models to explain the mechanism of the immunomod-
ulatory effects of many mycobacterial extracts and components
have been reported. These include cell activation by intracellu-
lar signals transduced by TLRs. The results of the present study
indicate that the activity of ABH to induce IL-12 production is
dependent on CD14 and TLR4 (Fig. 5). LPS causes activation
of Mo/M  via the CD14/TLR4/MD2 receptor complex (31).
The Limulus activity of ABH was 80 pg/ml, equivalent to E.coli
LPS (data not shown). Therefore, the endotoxin content in
the ABH used in the present study was  1 pg/ml, which was
completely inactive in our system. On the other hand,
polymyxin B-treated ABH also induced IL-12 production at
almost the same level as untreated ABH (Fig. 6). This excluded
the possibility that the activation of Mo/M  was due to response
to contamination of the ABH extract by LPS.
TLR2 was also reported to be a signal transducer for
components of fungi (11,12,32). The anti-TLR2 mAb TL2.1
did not inhibit induction of IL-12 production by ABH.
Figure 7. Oral administration of ABH enhanced NK cytotoxic activity in the
spleen. The indicated amounts of ABH were administered for 21 consecutive
days. Control mice were administered water. NK activity of spleen cells was
quantified using CytoTox96 reagent (Promega). Results are expressed as
means   SEM, n   6.
Figure 6. Influence of polymyxin B on IL-12-inducing activity of ABH. ABH
(0.17 ng/ml) and reference LPS (10 ng/ml) were pre-treated with 5  g
of polymyxin B for 30 min, and then used to stimulate PBMC for 16 h. The
IL-12 secreted into the supernatant was measured by ELISA.Agaricus blazei is rich in polysaccharides that can stimulate
immune cells. One of these,  -1,6-D-glucan, has been reported
to be the main component responsible for this activity. Ohno
et al. demonstrated that the functional centre of  -1,6-D-
glucan is a region rich in  -1,3 links (33–35).  -Glucans acti-
vate cells via TLR2 (32). The mannan fraction from Candida
albicans and Saccharomyces cerevisiae induced TNF-  produc-
tion in a manner dependent on CD14 and TLR4 (36). TLR4
is also involved in pattern recognition of soluble branched
 -(1,4)-glucans from Acetobacter AC-1 (37).
We speculate on two possible explanations for this observa-
tion:  -Glucan in ABH may be recognised by a different recep-
tor complex, or other components, such as mannan, may be
mainly responsible for the IL-12-inducing activity of ABH. As
ABH is a mixture of various components, it is necessary to iden-
tify and isolate the elements responsible for the action of ABH.
Some studies of the anti-tumor effects of A.blazei have
demonstrated direct cytotoxic effects (1). The chloroform/
methanol extracts of A.blazei were shown to have antitumor
activity against solid tumors. Ergosterol in this extract inhibits
angiogenesis and causes the death of tumor cells by preventing
neovascularisation (5). When the particles from fruiting bodies
of A.blazei Murill (ABP-F) were reacted with human serum,
the formation of complement-opsonised ABP, iC3b-ABP-F
complexes, and binding of the complexes to human PBMCs
were observed. In addition, PBMCs incubated in the presence
of iC3b-ABP-F complexes inhibited the proliferation of a
human tumor cell line in vitro (38).
These reports indicated that components of A.blazei have
various activities. It was reported that A.blazei extract acts
mainly through modulation of the immune system, activating
macrophages, neutrophils and lymphocytes (3,4,8). On the
other hand, ethanol extracts of A.blazei mycelia were shown to
reduce the cytopathic effects of the western equine encephalitis
(WEE) virus (39). Several fungi incubated with immune cells
showed activation of some cells, especially antigen-presenting
cells, and induced cytokine production (40–42,44–48). The
ethanol extracts of A.blazei stimulated macrophages and
induced expression of the cytokines IL-8 and TNF (49).
This report indicates that the extract of A.blazei mycelia
induces IL-12 production. IL-12 exerts multiple biological
activities, which include activation of CD8  CTLs, differenti-
ation of CD4  T lymphocytes, induction of nitorogen oxide
production by macrophages, induction of type 1 responses by
helper T lymphocytes and NK cell activation (50,51). IL-12 has
also been shown to possess potent antitumor activity in a wide
variety of murine tumor models (49,52–55). Recent reports
have demonstrated that the in vivo antitumor capacity of IL-12
is mediated via NK and/or NKT cells (56,57). The findings of
the present study will help in furthering our understanding of
the immunomodulatory and anti-viral effects of A.blazei. IL-12
promotes and sustains the cellular immune system. Oral admin-
istration of ABH was shown to enhance the NK activity of
mouse spleen cells (Fig. 7). It is notable that ABH modulates
immune responses not only in vitro but also in vivo. In the
context of A.blazei administration as a functional food, the
induction of IL-12 and enhancement of cellular immunity are
important for various biological activities.
In conclusion, we have demonstrated that hemicellulase-
derived ABH induces IL-12 production by human peritoneal
monocytes via TLR4-CD14 and enhances cytotoxic activity
against tumor cells in vivo. These responses may be involved
in the biological activities of ABH, such as its anti-tumor, anti-
infection and anti-allergic effects. ABH is a non-proliferative
and non-pathogenic microbial component that can trigger an
immune response that is useful in the fight against infectious
diseases and cancer. The accumulation of such data concern-
ing the effects of components and clarification of mechanisms
of their action are essential to understand features of mush-
room such as the biological response modifier (BRM).
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